These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 11693316)

  • 1. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
    Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
    Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
    J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
    Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
    Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
    Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.
    Rudolph RE; Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
    J Natl Cancer Inst; 2003 May; 95(10):750-7. PubMed ID: 12759393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus.
    Dolan K; Morris AI; Gosney JR; Field JK; Sutton R
    J Gastroenterol Hepatol; 2003 Jun; 18(6):683-9. PubMed ID: 12753151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers in Barrett's esophagus.
    Reid BJ; Blount PL; Rabinovitch PS
    Gastrointest Endosc Clin N Am; 2003 Apr; 13(2):369-97. PubMed ID: 12916666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.
    Reid BJ; Levine DS; Longton G; Blount PL; Rabinovitch PS
    Am J Gastroenterol; 2000 Jul; 95(7):1669-76. PubMed ID: 10925966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barrett's esophagus: a model of human neoplastic progression.
    Neshat K; Sanchez CA; Galipeau PC; Cowan DS; Ramel S; Levine DS; Reid BJ
    Cold Spring Harb Symp Quant Biol; 1994; 59():577-83. PubMed ID: 7587115
    [No Abstract]   [Full Text] [Related]  

  • 11. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.
    Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
    Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):745-52. PubMed ID: 12163328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma.
    Suspiro A; Pereira AD; Afonso A; Albuquerque C; Chaves P; Soares J; Leitão CN
    Am J Gastroenterol; 2003 Apr; 98(4):728-34. PubMed ID: 12738448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
    Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ
    PLoS Med; 2007 Feb; 4(2):e67. PubMed ID: 17326708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort.
    Reid BJ; Blount PL; Rubin CE; Levine DS; Haggitt RC; Rabinovitch PS
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1212-9. PubMed ID: 1551528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus.
    Dolan K; Garde J; Walker SJ; Sutton R; Gosney J; Field JK
    Hum Pathol; 1999 Dec; 30(12):1508-14. PubMed ID: 10667431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma.
    Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
    Gastroenterology; 1987 Jul; 93(1):1-11. PubMed ID: 3582897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus.
    Galipeau PC; Cowan DS; Sanchez CA; Barrett MT; Emond MJ; Levine DS; Rabinovitch PS; Reid BJ
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7081-4. PubMed ID: 8692948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.
    Li X; Galipeau PC; Sanchez CA; Blount PL; Maley CC; Arnaudo J; Peiffer DA; Pokholok D; Gunderson KL; Reid BJ
    Cancer Prev Res (Phila); 2008 Nov; 1(6):413-23. PubMed ID: 19138988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.